Skip to main content

What the FDA labels say about taking them together

Lenalidomide and tafasitamab

Tafasitamab's FDA label of February 2, 2026 names lenalidomide in its warnings and precautions section; the lenalidomide label PlainMeds reads does not name tafasitamab. The tafasitamab label: “The combination of MONJUVI with lenalidomide is contraindicated in pregnant women because lenalidomide can cause birth defects and death of the unborn child.”

Check it at the source: the lenalidomide FDA label on DailyMed (effective March 24, 2023, Celgene Corporation); the tafasitamab FDA label on DailyMed (effective February 2, 2026).

What does the lenalidomide label say about tafasitamab?

Lenalidomide's label (effective March 24, 2023) does not name tafasitamab in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Revlimid), NDA021880 (Bristol Myers Squibb), as published by Celgene Corporation, effective March 24, 2023 (SPL set 5fa97bf5-28a2-48f1-8955-f56012d296be), via openFDA; the full label on DailyMed

What does the tafasitamab label say about lenalidomide?

Tafasitamab label, warnings and precautions

The combination of MONJUVI with lenalidomide is contraindicated in pregnant women because lenalidomide can cause birth defects and death of the unborn child.

Source: FDA drug label (MONJUVI), Incyte Corporation, effective February 2, 2026 (SPL set ec13ac6b-bfde-4e84-907a-83bd69584d95), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

18Lenalidomide generic labelers
0Tafasitamab generic labelers
LenalidomideTafasitamab
Labeled forLeukemia, lymphoma and myeloma, AnemiaLeukemia, lymphoma and myeloma
Boxed warningYesNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?